Drugs / Urbagen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07270549 | Nov 2025 → Dec 2032 expected | CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy | CTNNB1 Foundation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Urbagen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07270549 ↗ |
| Action | Restore | “designed to restore functional CTNNB1 expression” NCT07270549 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV9 mediated gene replacement therapy (Urbagen)” NCT07270549 ↗ |
| Target | CTNNB1 | “Urbagen is an investigational gene addition therapy designed to restore functional CTNNB1 expression” NCT07270549 ↗ |